2Q5 Stock Overview
A pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Renovaro Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.49 |
| 52 Week High | US$3.14 |
| 52 Week Low | US$0.41 |
| Beta | 0.54 |
| 11 Month Change | 3.24% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -94.36% |
| 5 Year Change | -90.13% |
| Change since IPO | -91.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2Q5 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.8% |
| 1Y | n/a | -16.9% | 9.1% |
Return vs Industry: Insufficient data to determine how 2Q5 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 2Q5 performed against the German Market.
Price Volatility
| 2Q5 volatility | |
|---|---|
| 2Q5 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2Q5's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 2Q5's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 25 | David Weinstein | renovarobio.com |
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.
Renovaro Inc. Fundamentals Summary
| 2Q5 fundamental statistics | |
|---|---|
| Market cap | €78.49m |
| Earnings (TTM) | -€110.23m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs 2Q5 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2Q5 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$115.69m |
| Earnings | -US$115.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.73 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.8% |
How did 2Q5 perform over the long term?
See historical performance and comparison